SS
PCVX icon

Sunbelt Securities’s Vaxcyte PCVX Stock Holding History

Sunbelt Securities’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$58 Buy
+1
New +$54 ﹤0.01% 2752

Other funds holding PCVX

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sunbelt Securities's PCVX Position: Q1 2026 in Review

Sunbelt Securities opened a new position in Vaxcyte (PCVX) in Q1 2026: 1 share worth $58. The stake represents ﹤0.01% of the portfolio and ranks #2752 among its holdings.

336 funds tracked by Wall St. Rank hold PCVX as of Q1 2026.

  • Sunbelt Securities held 1 share of Vaxcyte worth $58 as of Q1 2026.
  • Vaxcyte was a new Sunbelt Securities position in Q1 2026.
  • Vaxcyte made up ﹤0.01% of Sunbelt Securities's portfolio in Q1 2026, its #2752 holding.
  • 336 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2026.

Based on Sunbelt Securities's 13F filing for Q1 2026, filed 18 May 2026.